야마토동영상 24.rkt365.top 바로가기 바다이야기 게임 방법
야마토동영상 26.rkt365.top 바다이야기 게임 방법
야마토동영상 99.rkt365.top 바다이야기 게임 방법
야마토동영상 2.rkt365.top 바다이야기 게임 방법
야마토동영상 4.rkt365.top 바다이야기 게임 방법
야마토동영상 97.rkt365.top 바다이야기 게임 방법
야마토동영상 21.rkt365.top 바다이야기 게임 방법
야마토동영상 53.rkt365.top 바다이야기 게임 방법
야마토동영상 57.rkt365.top 바다이야기 게임 방법
야마토동영상 16.rkt365.top 바다이야기 게임 방법
야마토동영상 16.rkt365.top 바다이야기 게임 방법
슬롯버프 온라인황금성 슬롯머신 원리 오션슬롯 다빈치게임 모바일게임 키지노릴게임 온라인삼국지 오토 슬롯머신게임 황금성3 바다이야기기계 릴게임판매 강원랜드 슬롯머신 잭팟 체리마스터게임 슬롯머신 777 야마토3 신천지무료 바다이야기 상어 놀이터 릴박스 몰게임 바다이야기 먹튀 신고 슬롯무료체험 실시간바둑이 황금성게임동영상 뽀빠이놀이터릴게임 백경게임 하는곳주소 다모아릴게임 PC 릴게임 오션파라 다이스게임 하는법 프라그마틱무료메타2 빠징코 슬롯머신 카카오 야마토 먹튀 릴게임 꽁머니 바다이야기릴게임사이트추천및안내 배터리게임 알라딘 바다이야기하는곳 파칭코하는법 프라그마틱 슬롯 종류 릴게임 바다신게임 최신 릴게임 바다이야기 무료체험 바다이야기 코드 우주전함야마토2205 바다이야기무료 릴게임 체리마스터 온라인파칭코 오리 지날야마토 무료바다이야기 로드할 오공슬롯 슬롯머신 기계 구입 바다이야기 게임 상품권릴게임 다빈치 릴게임 먹튀 무료슬롯체험 알라딘꽁머니 매장판황금성 바다이야기동영상 황금성게임공략방법 온라인 야마토 게임 빠칭코 슬롯머신 오리지널야마토2게임 슬롯머신 코딩 야마토2 pc버전 릴게임황금성오션바다 온라인 야마토 게임 황금성먹튀 슬롯총판 야마토2릴게임 오리지널 바다이야기 다모아릴게임 온라인파칭코 황금성 게임 장주소 오리지널야마토 바다이야기확률 릴게임손오공하는법 10원야 마토 바다이야기 먹튀사이트 바다이야기 코드 릴게임사이트 릴게임놀이터 오션슬롯먹튀 슬롯추천 무료충전릴게임 무료슬롯머신 한게임바둑이 스핀모바게임랜드 황금성매장 손오공게임하기 바다이야기파칭코 오리지날황금성9게임 황금성갈갈이 체리마스터 비법 슬롯머신 알고리즘 오리지널바다이야기 알라딘게임 황금성게임 바다이야기 공략법 릴황금성 백경다운로드 바다이야기 시즌7 야마토3게임공략법 프라그마틱 슬롯 하는법 황금성포커 바다이야기다운로드 인터넷야마토릴게임 바다이야기 릴게임 사이트 추천 및 안내 릴게임 온라인 씨엔조이 황금성온라인 바다이야기하는곳 무료황금성 바다이야기릴게임 황금성갈가리 오션파라다이스예시 바다이야기프로그램 온라인릴게임 야마토다운로드 릴게임 다빈치 릴게임손오공하는법 무료머니릴게임 pc빠찡꼬게임 바다이야기기계 야마토2게임 이 기사는 2025년10월22일 08시07분에 팜이데일리 프리미엄 콘텐츠로 선공개 되었습니다.
[Shin-Min Joon, Edaily Reporter] On October 21 shares of HansBiomed, HLB and NIBEC stood out in the South Korean biopharmaceutical stock market each recording double digit gains compared to the previous trading day.
HansBiomed’s stock rose on growing momentum for its extracellular matrix (ECM) based ski 통대환 n booster. HLB gained after news broke that its liver cancer drug could expand its treatment scope from advanced to surgically resectable cases as reported in an international medical journal. Meanwhi 주부빠른대출 le NIBEC saw its shares climb on expectations for the U.S. expansion of its next generation periodontal tissue regeneration material.
HansBiomed stock tr 개인회생인가전대출 end on Oct 21.(Image=MP Doctor)
HansBiomed Soars on ECM Skin Booster Outlook
HansBiomed shares surged 16.74% to 27,200 won on the back 대출원금상환 of growing expectations for its extracellular matrix (ECM) skin booster Celluderm. The company a bioengineering firm focused on human tissue transplants and medical devices has positioned Celluderm a 개인파산자대출가능한곳 s a next generation skin rejuvenation product.
Unlike traditional skin boosters that stimulate collagen indirectly Celluderm utilizes human derived acellular dermal matrix (hADM) to directly replenish collagen. Designed with ultra fine 75㎛ particles Celluderm ensures even and abundant collagen delivery.
HansBiomed the first domestic company to establish a tissue bank in Korea, is recognized for its expertise and reliability in tissue transplantation. Its proprietary processing technology minimizes immune-reactive agents, enhancing biocompatibility and reducing side effects.
The company has expanded its target number of domestic hospitals adopting Celluderm to 4000. As a result it has revised its 2025 sales goal from 3 to 4 billion won to between 25 and 30 billion won.
HansBiomed also plans to expand exports to Japan and China. In Japan, where regulatory hurdles are minimal, sales are expected to begin soon. In China, the company is in the process of obtaining medical device approval.
A company representative noted “The upward revision of our sales target has likely bolstered investor sentiment. Celluderm is not just a skin enhancer it aims to fundamentally rejuvenate the skin using ECM technology.” They added “With Celluderm Hans Biomed seeks to pioneer a new category of skin boosters globally.”
HLB Gains on Expanded Use Case for Liver Cancer Drug
HLB’s stock jumped 11.17% to 45,800 won after announcing new clinical trial results supporting broader applications for its liver cancer therapy. The combination of its targeted anti cancer drug Rivoceranib with Hengrui’s immunotherapy Camrelizumab has shown promising results not only for advanced hepatocellular carcinoma (HCC) but also for patients eligible for surgery.
The findings recently published in The Lancet demonstrated that the combination therapy more than doubled event free survival (EFS) to 42.1 months compared to 19.4 months for surgery alone. Major pathological response (MPR) rates were also significantly higher at 35% versus 8%.
The phase 2/3 trial conducted at 16 hospitals across China enrolled 294 patients with resectable HCC who had moderate to high risk of recurrence. Patients were randomly assigned to surgery alone or to receive the combination therapy before and after surgery.
Serious treatment related adverse events (Grade 3 or higher) occurred in 38% of patients receiving the combination therapy consistent with known safety profiles for such treatments.
An HLB official said “This is the first time a global phase 3 study has confirmed the efficacy of combining immunotherapy with targeted therapy in both pre and post operative settings.”
They added, “This suggests a paradigm shift in liver cancer treatment beyond surgical monotherapy.”
Hengrui plans to resubmit its New Drug Application (NDA) to the U.S. FDA between December 2025 and January 2026. Depending on the classification (Class 1 or 2) the FDA is expected to issue a decision within 2 to 6 months of submission.
NIBEC Eyes U.S. Market with Next Gen Periodontal Regenerative Material
NIBEC’s share price rose 12.64% to 41,450 won on optimism surrounding its U.S. expansion strategy. The company is seeking FDA approval for its next generation decellularized biomaterial, designed to support gum tissue regeneration following tooth extraction and bone grafting procedures.
NIBEC recently showcased the material at the American Academy of Periodontology (AAP) 2025 in Toronto. This marked its first official participation and was part of a broader strategy to build clinical credibility and market presence in the U.S.
The company aims to establish a U.S. foothold through collaboration with key opinion leaders (KOL) in regenerative medicine. NIBEC also plans to present its BBB (blood brain barrier) shuttle platform at the Central Nervous System Drug Delivery Conference on December 10.
Earlier this year, NIBEC secured a licensing deal worth $435 million (595.3 billion won) with a U.S.based biopharma company.
A NIBEC spokesperson stated “Our participation in the AAP event is a strategic step to build global clinical trust in periodontal regeneration adding that this effort is expected to contribute significantly to future revenue growth.”
신민준 (adonis@edaily.co.kr)
조회 : 0
